| Document |
Document Title |
|
WO/2014/100327A1 |
Disclosed is a process for the production of high purity alpha-tocotrienol from palm oil extract. More particularly, the invention relates to a process for the separation of alpha-tocotrienol from a mixtures of other tocotrienols and toc...
|
|
WO/2014/097170A1 |
The present invention relates to a process of the asymmetric hydrogenation of an unsaturated ketone or aldehyde by molecular hydrogen in the presence of at least one chiral iridium complex and in the presence of at least one additive and...
|
|
WO/2014/098046A1 |
A method for producing a compound represented by formula (2) or a salt thereof, characterized in that a compound represented by formula (1) or a salt thereof is reacted with 2,2-dialkoxypropane or isopropenyl alkyl ether in the presence ...
|
|
WO/2014/092175A1 |
The present invention addresses the problem of providing a method for manufacturing a comparatively high-purity ≥4-mer polyphenol by precisely isolating said ≥4-mer polyphenol from a polyphenol mixture. This method for manufacturing ...
|
|
WO/2014/090832A1 |
The invention concerns a tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin, the covalent coupling is formed as an ester or e...
|
|
WO/2014/086099A1 |
The invention relates to a C-aryl substituted glucopyranosyl derivative as an inhibitor of sodium dependent glucose transporter (SGLTs), the preparation method and the medical use thereof, in particular the glucopyranosyl derivative show...
|
|
WO/2014/087100A1 |
The invention relates to the use of at least one biotin molecule grafted with at least one molecule M for determining the presence and/or metering the amount in a solution of an element E selected among the following metals: mercury, lea...
|
|
WO/2014/083226A1 |
The present invention relates to the design of haptens that are structurally related to coumarin oral anticoagulant compounds (COAC), to be used for the production of specific antibodies against said type of substances and the subsequent...
|
|
WO/2014/075563A1 |
Disclosed is a preparation method of antimicrobial traditional Chinese medicine compound total flavonoid. The traditional Chinese medicine compound total flavonoid prepared by using the method has an antimicrobial effect. Also disclosed ...
|
|
WO/2014/074365A1 |
The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridem...
|
|
WO/2014/071438A1 |
This invention relates to polyphenolic compounds, in particular ethoxylated polyphenolic compounds and the use of such compounds in disease prevention, disease treatment, and life extension in humans and animals. The invention also relat...
|
|
WO/2014/072017A1 |
The application relates to a compound of a formula (I) which is suitable for use as a functional material in electronic devices.
|
|
WO/2014/071480A1 |
The present invention describes a method for fractionating an R. mangle extract, by means of which it is possible to efficiently concentrate a significant quantity of complex tannins. The fraction obtained by means of the proposed method...
|
|
WO/2014/074845A1 |
A photoactive coumarin monomer includes a substituted coumarin molecule that has at least two functional groups may be used to produce a polymer with a coumarin unit or a coumarin derivative unit as part of the polymer backbone. The poly...
|
|
WO/2014/071369A1 |
The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have a...
|
|
WO/2014/070108A1 |
A fluorescent rosamine dye having specificity for neural stem cells, specifically, proliferative neural stem cells, and represented by Structural Formula (I): wherein X is an anion, is described herein. Synthesis of the fluorescent rosam...
|
|
WO/2014/071363A1 |
The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have a...
|
|
WO/2014/071134A1 |
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embod...
|
|
WO/2014/063504A1 |
Provided in the present invention is a method for extracting dihydroquercetin from the root of larch trees in a specific regions, by utilizing the resource advantage that the root (200 mm below the earth surface) of tree species has a re...
|
|
WO/2014/064716A1 |
An embodiment of the present invention pertains to molecules of general formula A and formula B, namely substituted hexahydro-(5H)-1-benzopyran-5-one (or hexahydro-(5H)-chromen-5-one) derivatives and substituted tetrahydro-(5H)-1- benzop...
|
|
WO/2014/061752A1 |
A compound characterized in being represented by any of general formulae (1) to (5); a tautomer or a geometric isomer thereof; a salt of the compound, tautomer, or geometric isomer; and the like. (In the formulae, X1 represents a single ...
|
|
WO/2014/062965A1 |
The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modula...
|
|
WO/2014/061764A1 |
A compound having an exceptional blood-sugar-reducing effect and represented by general formula (I), and a pharmaceutically acceptable salt thereof. In the formula, X is =C(R8)-, -CH(R8)-, =N-, or -O-; Y is =C(R9)-, -CH(R9)-, or =N-; Z i...
|
|
WO/2014/056038A1 |
The present disclosure provides a compound of the following formula, racemates, enantiomers, prodrugs and salts thereof: Formula (I). Also provided is the use of these compounds for the treatment of ischemia and reperfusion injuries. Fur...
|
|
WO/2014/057727A1 |
The purpose is to provide a method for manufacture a fraction containing nobiletin and tangeretin in high concentration and having excellent safety, economic efficiency, and commercialization. The above-stated purpose is achieved by a me...
|
|
WO/2014/058274A1 |
The present invention relates to a production method for induced-pluripotent-stem-cell-derived differentiated cells, from which undifferentiated induced pluripotent stem cells (iPS) have been eliminated, the method comprising the steps o...
|
|
WO/2014/059228A1 |
Aqueous compositions comprising at least one hydrotrope and at least one active compound. The at least one hydrotrope is present in an amount: (a) effective to solubilize said at least one active compound in water; and/or (b) effective t...
|
|
WO/2014/057103A1 |
Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.
|
|
WO/2014/054174A1 |
A method for producing a low-polymerization-degree proanthocyanidin, comprising heating an aqueous solution of a proanthocyanidin raw material at a low temperature in the presence of a compound containing a sulfo group to produce a natur...
|
|
WO/2014/054785A2 |
The present invention provides an in-plane switching-type liquid crystal display element imparted with a high-efficiency alignment control function, and having excellent burn-in properties. The present invention also provides a manufactu...
|
|
WO/2014/053460A1 |
The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in suc...
|
|
WO/2014/048313A1 |
Disclosed are a compound as represented by formula (I), which is a condensation product of a theanine derivative and a carboxylic acid coumarin derivative, a compound as represented by formula (II), which is an intermediate of the conden...
|
|
WO/2012/154676A9 |
The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have a...
|
|
WO/2014/046224A1 |
The purpose of the invention is to provide a novel coumarin derivative or pharmaceutically acceptable salt thereof and a drug containing this compound as an active ingredient. This coumarin derivative or pharmaceutically acceptable salt ...
|
|
WO/2014/041125A1 |
The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promoting cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in pat...
|
|
WO/2014/038221A1 |
The present invention provides: a method that is for preparing a crystal structure analysis sample resulting from an organic compound molecule that determines molecular structure being regularly arranged within hollows and minute pores w...
|
|
WO/2014/038220A1 |
The present invention is: a guest-compound-enveloping polymer-metal-complex crystal characterized by at least one selected from an aliphatic hydrocarbon, an alicyclic hydrocarbon, an ether, an ester, an aromatic hydrocarbon, a halogenate...
|
|
WO/2014/032183A1 |
A compound of formula (I) as well as pharmaceutical compositions comprising same is provided. An extract of a plant belonging to a species of Populus, the extract comprising this compound is also provided. These can be used as antibacter...
|
|
WO/2014/031784A1 |
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating...
|
|
WO/2014/030006A1 |
Cellulosic fibrous materials are described which are impregnated with a bioflavonoid composition, the bioflavonoid content of the composition comprising at least naringin and neohesperidin. The use of such impregnated materials is also d...
|
|
WO/2014/031762A1 |
Provided are benzocyclooctyne compounds of formula (I). These compounds undergo strain-promoted azide-alkyne cyclo additions (SPAAC) without presence of toxic metal catalysts. The provided compounds are useful for diagnosis and imaging o...
|
|
WO/2014/031755A1 |
Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivativ...
|
|
WO/2014/030688A1 |
The purpose of the present invention is to provide a compound having bone formation promoting activity. The solution is a compound having general formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 is a methyl ...
|
|
WO/2014/030053A1 |
Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.
|
|
WO/2014/030005A1 |
Polymeric materials are described which have a bioflavonoid coating, the bioflavonoid content of the coating comprising at least naringin and neohesperidin. The use of such coated polymeric materials is also described as well as the proc...
|
|
WO/2014/028025A1 |
Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula (I) wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selecte...
|
|
WO/2014/025651A1 |
Chroman compounds and derivatives of Formula (I) are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical composit...
|
|
WO/2014/025370A1 |
A method of quenching excited state energy from a photodegradable pigment that has been excited by absorption of light having a wavelength in the wavelength range of 290 - 800 nm, comprising reacting a pigment with a conjugated fused tri...
|
|
WO/2014/023846A1 |
The present invention relates to a method of preparing a tocopherol or protected tocopherol with a reduced content of phenolic compound or protected phenolic compound, particularly of (2R,3R)-2,3,4,6,7-pentamethyl-2- (4,8,12-trimethyltri...
|
|
WO/2014/023845A1 |
The present invention relates to a method of preparing a tocopherol or protected tocopherol with a reduced content of dehydrotocopherol or protected dehydrotocopherol comprising the step of contacting tocopherol or protected tocopherol i...
|
